If the plan pans out, it would be an enormous boon to Eli Lilly and Novo Nordisk. Currently, many health insurance plans, as ...

Flush with Trump connections, Ballard Partners is D.C.’s new lobbying powerhouse — and its clients are reaping the benefits.

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

When Robyn Yerian founded The Bird’s Nest back in 2022, affordability was her main concern. Yerian — divorced, mother of two, ...

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

The Trump administration is launching a pressure campaign against prescription drugmakers in an effort to get them to lower ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

In the letters, Trump gave the pharmaceutical firms until Sept. 29 to make a series of commitments that aim to provide “immediate relief from the vastly inflated drug prices and put an end to the free ...

Medicare Advantage usage trends reveal slight declines in 2023, highlighting critical insights for policymakers amid rising ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...